Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
5 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Galmed Pharmaceuticals Ltd.’s names, not what it holds today.
Patents granted
5
5 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against none in 2024 and 1 in 2023
Applications published
20
1 of them in 2025
Names they are printed under
3
a subsidiary
By yearGrantedApplications published
'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
GALMED RESEARCH AND DEVELOPMENT LTD a subsidiary
IL, as the owner printed on each patent. 4 more under the same name are not counted (printed in NI, printed in IE)
11 publishedOnKai Inc. a subsidiary
named as the applicant on its applications, in US
7 publishedGALMED RESEARCH AND DEVELOPMENT LTD a subsidiary
named as the applicant on its applications, in IL
2 publishedNames not counted (1)
Galmed International Ltd.
Most of its patents print CM; this name counts in MT. 5 granted and 2 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Mar 4, 2025 | 12,239,712 | Combination therapy for the treatment of liver disease | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Feb 7, 2023 | 11,571,431 | Aramchol salts | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Dec 14, 2021 | 11,197,870 | Treatment for hepatic fibrosis | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Nov 9, 2021 | 11,166,964 | Treatment for modulating gut microbiota | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Dec 1, 2020 | 10,849,911 | Low dose compositions of Aramachol salts | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Oct 30, 2025 | 2025/0332176 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Jun 27, 2024 | 2024/0211885 | SMART CONTRACT COMPLIANCE MONITORING TO ENABLE REMOTE COLLABORATION | IT methods for management | OnKai Inc. |
| May 2, 2024 | 2024/0145074 | SMART CONTRACT COMPLIANCE MONITORING TO ENABLE REMOTE COLLABORATION | IT methods for management | OnKai Inc. |
| May 2, 2024 | 2024/0145073 | QUANTIFYING UNMET NEEDS THROUGH INTERNET SCRAPING | IT methods for management | OnKai Inc. |
| May 2, 2024 | 2024/0144120 | ELECTRONIC TEAM BUILDING AMONG UNCONNECTED ENTITIES | IT methods for management | OnKai Inc. |
| May 2, 2024 | 2024/0143673 | INTERNET SCRAPING TO DEVELOP A PLAN FOR SOLVING AN UNMET NEED | IT methods for management | OnKai Inc. |
| May 2, 2024 | 2024/0143672 | EPHEMERAL SOCIAL NETWORKS | IT methods for management | OnKai Inc. |
| Apr 25, 2024 | 2024/0135291 | GENERATING EVOLVING UNMET NEED MAPS | IT methods for management | OnKai Inc. |
| Nov 17, 2022 | 2022/0362263 | TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD |
| Nov 4, 2021 | 2021/0338826 | COMBINATION THERAPY FOR THE TREATMENT OF LIVER DISEASE | Pharmaceuticals | GALMED RESEARCH AND DEVELOPMENT LTD · patent 12,239,712 granted from it |
What it applied for, 2024 to 2025: IT methods for management 7 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.